TrialClinical and translational science2025

Safety, Tolerability, and Pharmacokinetics of NIM-1324 an Oral LANCL2 Agonist in a Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.

Andrew Leber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.